Literature DB >> 11402109

A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.

M F Brin1, K E Lyons, J Doucette, C H Adler, J N Caviness, C L Comella, R M Dubinsky, J H Friedman, B V Manyam, J Y Matsumoto, S L Pullman, A H Rajput, K D Sethi, C Tanner, W C Koller.   

Abstract

OBJECTIVE: To evaluate the safety and efficacy of botulinum toxin type A injection in essential tremor of the hand.
BACKGROUND: Botulinum toxin type A is an effective treatment for dystonia, spasticity, and other movement disorders and has been found to be useful in open-label studies and one double-masked study of essential hand tremor.
METHODS: One hundred thirty-three patients with essential tremor were randomized to low-dose (50 U) or high-dose (100 U) botulinum toxin type A (Botox) or vehicle placebo treatment. Injections were made into the wrist flexors and extensors. Patients were followed for 16 weeks. The effect of treatment was assessed by clinical rating scales, measures of motor tasks and functional disability, and global assessment of treatment. Hand strength was evaluated by clinical rating and by a dynamometer.
RESULTS: Both doses of botulinum toxin type A significantly reduced postural tremor on the clinical rating scales after 4 to 16 weeks. However, kinetic tremor was significantly reduced only at the 6-week examination. Measures of motor tasks and functional disability were not consistently improved with botulinum toxin type A treatment. Grip strength was reduced for the low- and high-dose botulinum toxin type A groups as compared with the placebo group. Adverse reactions consisted mainly of dose-dependent hand weakness.
CONCLUSION: Botulinum toxin type A injections for essential tremor of the hands resulted in significant improvement of postural, but not kinetic, hand tremors and resulted in limited functional efficacy. Hand weakness is a dose-dependent significant side effect of treatment at the doses used in this study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402109     DOI: 10.1212/wnl.56.11.1523

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  58 in total

Review 1.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 2.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

3.  Chronic embedded cortico-thalamic closed-loop deep brain stimulation for the treatment of essential tremor.

Authors:  Enrico Opri; Stephanie Cernera; Rene Molina; Robert S Eisinger; Jackson N Cagle; Leonardo Almeida; Timothy Denison; Michael S Okun; Kelly D Foote; Aysegul Gunduz
Journal:  Sci Transl Med       Date:  2020-12-02       Impact factor: 17.956

Review 4.  Differential diagnosis of common tremor syndromes.

Authors:  R Bhidayasiri
Journal:  Postgrad Med J       Date:  2005-12       Impact factor: 2.401

Review 5.  Essential tremor.

Authors:  Joaquim Jos Ferreira; Cristina Sampaio
Journal:  BMJ Clin Evid       Date:  2007-05-01

Review 6.  Botulinum toxin for symptomatic therapy in multiple sclerosis.

Authors:  Michelle H Cameron; Francois Bethoux; Nina Davis; Meredith Frederick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

7.  A patient with tremor, part 2: from diagnosis to treatment.

Authors:  Hrishikesh Kumar; Mandar Jog
Journal:  CMAJ       Date:  2011-08-15       Impact factor: 8.262

Review 8.  Benefits and risks of pharmacological treatments for essential tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa; Cynthia L Comella; Mahmood S Eisa; Rodger J Elble; Stanley Fahn; Joseph Jankovic; Jorge L Juncos; William C Koller; William G Ondo; Kapil D Sethi; Matthew B Stern; Caroline M Tanner; Ron Tintner; Ray L Watts
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

10.  Overview of essential tremor.

Authors:  Theresa A Zesiewicz; Abinaya Chari; Israt Jahan; Amber M Miller; Kelly L Sullivan
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.